Virtu Financial’s Palvella Therapeutics PVLA Stock Holding History

Virtu Financial’s Portfolio PVLA Stock Details PVLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-7,726	Closed	-$963K	–	2388
2026 Q1	$963K	Buy	+7,726	New	+$806K	0.04%	316
2024 Q1	–	Sell	-1,126	Closed	-$16K	–	2219
2023 Q4	$16K	Buy	+1,126	New	+$20.6K	﹤0.01%	1355
2022 Q4	–	Sell	-171	Closed	-$16K	–	2236
2022 Q3	$16K	Buy	+171	New	+$22K	﹤0.01%	1451
2021 Q1	–	Sell	-239	Closed	-$48K	–	2113
2020 Q4	$48K	Buy	+239	New	+$49.7K	0.01%	1238
2019 Q4	–	Sell	-809	Closed	-$221K	–	1931
2019 Q3	$221K	Buy	+809	New	+$313K	0.02%	915
2018 Q2	–	Sell	-643	Closed	-$352K	–	2585
2018 Q1	$352K	Buy	643 +281	+78%	+$174K	0.02%	933
2017 Q4	$219K	Sell	362 -4	-1%	-$1.86K	0.01%	1586
2017 Q3	$169K	Buy	+366	New	+$156K	0.01%	1925

Other funds holding PVLA

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Virtu Financial's PVLA Position: Q2 2026 in Review

Virtu Financial sold out of Palvella Therapeutics (PVLA) in Q2 2026, closing a stake of 7,726 shares — an estimated $963K sold.

Virtu Financial first reported a position in PVLA in Q3 2017 and held it in 8 quarters. The position peaked at $963K in Q1 2026. 196 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

Virtu Financial reported no remaining Palvella Therapeutics position as of Q2 2026 after selling out during the quarter.
Virtu Financial sold 7,726 Palvella Therapeutics shares in Q2 2026, an estimated $963K.
Virtu Financial first reported a position in Palvella Therapeutics in Q3 2017 and held it in 8 quarters.
Virtu Financial's Palvella Therapeutics position peaked at $963K in Q1 2026.
196 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on Virtu Financial's 13F filing for Q2 2026, filed 13 Aug 2026.